PRA Health Sciences (PRAH) has risen sharply, recording gains of 11.63% in the past 4 weeks. However, the stock has corrected -0.34% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 10.49% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 6.88% and the 50-Day Moving Average is 10.53%. PRA Health Sciences (NASDAQ:PRAH): stock turned positive on Friday. Though the stock opened at $48.81, the bulls momentum made the stock top out at $49.41 level for the day. The stock recorded a low of $48.665 and closed the trading day at $49.25, in the green by 0.84%. The total traded volume for the day was 632,882. The stock had closed at $48.84 in the previous days trading.
The company Insiders own 2.5% of PRA Health Sciences shares according to the proxy statements. Also, Equity Analysts at the Citigroup maintains the rating on PRA Health Sciences (NASDAQ:PRAH). The brokerage firm has issued a Buy rating on the shares. The Analysts at the ratings agency raises the price target from $53 per share to $55 per share. The rating by the firm was issued on August 1, 2016.
PRA Health Sciences, Inc. is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. The Company performs an array of services across the spectrum of clinical development programs, from the filing of investigational new drug (INDs) and similar regulatory applications to conducting all phases of clinical trials. Its service offerings include Product Registration Services, which includes Phase IIb through III product registration trials and Phase IV trials, inclusive of post-marketing commitments and registries; Strategic Solutions, which provides Embedded Solutions and functional outsourcing services, and Early Development Services, which includes Phase I through Phase IIa clinical trials and bioanalytical laboratory services.